Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
McKinsey
Chinese Patent Office
Johnson and Johnson
Chubb
Cantor Fitzgerald
US Army
Accenture
Baxter

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022201

« Back to Dashboard

NDA 022201 describes FIRMAGON, which is a drug marketed by Ferring and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the FIRMAGON profile page.

The generic ingredient in FIRMAGON is degarelix acetate. One supplier is listed for this compound. Additional details are available on the degarelix acetate profile page.
Summary for 022201
Tradename:FIRMAGON
Applicant:Ferring
Ingredient:degarelix acetate
Patents:3
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022201
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201 NDA Ferring Pharmaceuticals Inc. 55566-8303 N 55566-8303-1
FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201 NDA Ferring Pharmaceuticals Inc. 55566-8403 N 55566-8403-1

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;SUBCUTANEOUSStrengthEQ 80MG BASE/VIAL
Approval Date:Dec 24, 2008TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:May 18, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
Patent:➤ Try a Free TrialPatent Expiration:Apr 27, 2032Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING PROSTATE CANCER
Patent:➤ Try a Free TrialPatent Expiration:Feb 10, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
McKinsey
Johnson and Johnson
Daiichi Sankyo
Moodys
Julphar
QuintilesIMS
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.